ANALYSIS | PRODUCT INNOVATION |
FINDING A NEW NICHE IN FUNGAL NAIL TREATMENT
The fungal nail market, worth $1 billion globally, has been under-served ® and for clear reasons, says Moberg Derma CEO, president and co-founder Peter Wolpert. With new
technologies and an original business model, the Swedish company aims to change that, he tells Ashley Yeo
S
ASHLEY YEO, Principal Analyst, Informa Business Information
email
ashley.yeo@
informa.com
16 ❚
IX-YEAR-OLD MOBERG Derma passed a significant milestone in Q3 2011, by turning in an operating profit for the first time. Furthermore, the Stockholm, Sweden-
based producer of a new over-the-counter topical fungal nail treatment, and developer of a range of other potentially powerful cosmetic and skin treatments, is confident of further improvements on this performance as its range becomes better known in global markets. Its initial success is a result of its efforts
to get its launch product, the nail fungal treatment Nalox, its patented treatment of discoloured and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis, into the market. In September 2010, after 4 years of development, the product was launched in the Nordic countries, seen as the 'home market' of Moberg Derma.
Commercial development The company is small (some 20 staff at present), but has built ambitious expansion plans around, what its CEO and president, Peter Wolpert, describes as a fairly unique business model. In 2011, the company embarked on an intense period of partnering with larger companies, which has, to date, given it the potential to exploit a total of 50 geographic markets globally. Those markets include most of the European continent, where long-standing
March 2012 |
prime-journal.com
partner Meda (which launched Nalox in the Nordic countries), among others, will represent it; and the US, where in the second half of 2011, Moberg DermaÕs US distributor Alterna began taking orders for the product, including from the retail chain Walmart. In the US, Alterna markets it under its established Kerasal brand, as Kerasal Nail. In some other countries, it is known as Emtrix. This type of commercial adaptation is all part of Moberg DermaÕs strategy for penetrating markets with the Nalox franchise, and is likely to be the model for the future pipeline of new products being developed. This includes a second-generation nail fungal treatment. These products in development have a combined potential sales value of $3 billion, Mr Wolpert told an investor meeting late last year. For now, however, the commercial
focus is entirely on the launch product, which is described as a non-prescription topical nail product that has the potential to become the firstline treatment for common nail disorders. Moberg Derma says it has a unique and rapid mechanism of action, which brings visible improvements within 2–4 weeks of treatment. Nail fungus is the most common nail disease and affects approximately 10% of the general population, and increases with age. Dermatologist Eckhart Haneke1
wrote
in PRIME that onychomycosis increases in frequency with age, reaching up to
Ageing of
the nails, a relatively inconspicuous process, is the result of a general slow-down of the metabolism in older persons, impaired vascular supply, and decreased physical activity.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112